Review
. 2020 Dec; 21(23):.
doi: 10.3390/ijms21238984.

Overcoming Immune Evasion in Melanoma

Kevinn Eddy 1 Suzie Chen 1 
Affiliations
  • PMID: 33256089
  •     445 References
  •     21 citations

Abstract

Melanoma is the most aggressive and dangerous form of skin cancer that develops from transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is "curable" at this stage. However, after metastasis, it is difficult to treat and the five-year survival is only 25%. In recent years, a better understanding of the etiology of melanoma and its progression has made it possible for the development of targeted therapeutics, such as vemurafenib and immunotherapies, to treat advanced melanomas. In this review, we focus on the molecular mechanisms that mediate melanoma development and progression, with a special focus on the immune evasion strategies utilized by melanomas, to evade host immune surveillances. The proposed mechanism of action and the roles of immunotherapeutic agents, ipilimumab, nivolumab, pembrolizumab, and atezolizumab, adoptive T- cell therapy plus T-VEC in the treatment of advanced melanoma are discussed. In this review, we implore that a better understanding of the steps that mediate melanoma onset and progression, immune evasion strategies exploited by these tumor cells, and the identification of biomarkers to predict treatment response are critical in the design of improved strategies to improve clinical outcomes for patients with this deadly disease.

Keywords: T-VEC; adoptive T-cell therapy; anti-CTLA-4; anti-PD-1; anti-PD-L1; immune checkpoint blockade therapy; immunotherapy; melanoma; melanoma immune evasion.

M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
Monica Falleni, Federica Savi, +4 authors, Gaetano P Bulfamante.
Melanoma Res, 2017 Mar 09; 27(3). PMID: 28272106
Systemic Antitumor Effects and Abscopal Responses in Melanoma Patients Receiving Radiation Therapy.
Mark A D'Andrea, G Kesava Reddy.
Oncology, 2020 Feb 23; 98(4). PMID: 32079015
Review.
Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.
Fa-Xing Yu, Jing Luo, +14 authors, Kun-Liang Guan.
Cancer Cell, 2014 Jun 03; 25(6). PMID: 24882516    Free PMC article.
Highly Cited.
Transcriptional and epigenetic regulation of T cell hyporesponsiveness.
Renata M Pereira, Patrick G Hogan, Anjana Rao, Gustavo J Martinez.
J Leukoc Biol, 2017 Jun 14; 102(3). PMID: 28606939    Free PMC article.
Review.
Ethnic variation in melanin content and composition in photoexposed and photoprotected human skin.
Simon Alaluf, Derek Atkins, +3 authors, Alan Heath.
Pigment Cell Res, 2002 Apr 09; 15(2). PMID: 11936268
Incidence of noncutaneous melanomas in the U.S.
Colleen C McLaughlin, Xiao-Cheng Wu, +3 authors, Vivien W Chen.
Cancer, 2005 Jan 15; 103(5). PMID: 15651058
Highly Cited.
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
Isabel Poschke, Dimitrios Mougiakakos, +2 authors, Rolf Kiessling.
Cancer Res, 2010 May 21; 70(11). PMID: 20484028
Highly Cited.
Are growth phases exclusive to cutaneous melanoma?
C Urso.
J Clin Pathol, 2004 Apr 29; 57(5). PMID: 15113872    Free PMC article.
Reversal of ultraviolet radiation-induced immune suppression by recombinant interleukin-12: suppression of cytokine production.
D A Schmitt, J P Walterscheid, S E Ullrich.
Immunology, 2000 Sep 30; 101(1). PMID: 11012758    Free PMC article.
siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.
Willemijn Hobo, Frans Maas, +4 authors, Harry Dolstra.
Blood, 2010 Aug 05; 116(22). PMID: 20682852
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H Nishimura, T Okazaki, +8 authors, T Honjo.
Science, 2001 Feb 24; 291(5502). PMID: 11209085
Highly Cited.
KIT gene mutations and copy number in melanoma subtypes.
Carol Beadling, Erick Jacobson-Dunlop, +12 authors, Christopher L Corless.
Clin Cancer Res, 2008 Nov 05; 14(21). PMID: 18980976
Highly Cited.
How regulatory T cells work.
Dario A A Vignali, Lauren W Collison, Creg J Workman.
Nat Rev Immunol, 2008 Jun 21; 8(7). PMID: 18566595    Free PMC article.
Highly Cited. Review.
Restoring function in exhausted CD8 T cells during chronic viral infection.
Daniel L Barber, E John Wherry, +5 authors, Rafi Ahmed.
Nature, 2005 Dec 31; 439(7077). PMID: 16382236
Highly Cited.
KIT in melanoma: many shades of gray.
Ana Slipicevic, Meenhard Herlyn.
J Invest Dermatol, 2015 Jan 13; 135(2). PMID: 25573046    Free PMC article.
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
Richard C Koya, Stephen Mok, +8 authors, Antoni Ribas.
Cancer Res, 2012 Jun 14; 72(16). PMID: 22693252    Free PMC article.
Highly Cited.
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
Alena Gros, Maria R Parkhurst, +11 authors, Steven A Rosenberg.
Nat Med, 2016 Feb 24; 22(4). PMID: 26901407    Free PMC article.
Highly Cited.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.
David Escors.
New J Sci, 2014 Mar 19; 2014. PMID: 24634791    Free PMC article.
Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production.
C P Gray, A V Franco, P Arosio, P Hersey.
Int J Cancer, 2001 May 15; 92(6). PMID: 11351305
Nevus-associated melanomas: clinicopathologic features.
Danielle Shitara, Mauricio M Nascimento, +4 authors, Ediléia Bagatin.
Am J Clin Pathol, 2014 Sep 23; 142(4). PMID: 25239415
From melanocytes to melanomas.
A Hunter Shain, Boris C Bastian.
Nat Rev Cancer, 2016 Apr 30; 16(6). PMID: 27125352
Highly Cited. Review.
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.
Shawn D Blackburn, Haina Shin, +7 authors, E John Wherry.
Nat Immunol, 2008 Dec 02; 10(1). PMID: 19043418    Free PMC article.
Highly Cited.
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Robert H I Andtbacka, Howard L Kaufman, +26 authors, Robert S Coffin.
J Clin Oncol, 2015 May 28; 33(25). PMID: 26014293
Highly Cited.
Melanoma and sun exposure: contrasts between intermittent and chronic exposure.
J M Elwood.
World J Surg, 1992 Mar 01; 16(2). PMID: 1561794
Review.
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
Kimberly R Jordan, Rodabe N Amaria, +6 authors, Martin D McCarter.
Cancer Immunol Immunother, 2013 Sep 28; 62(11). PMID: 24072401    Free PMC article.
Studies on melanoma. II. Sex and survival in human melanoma.
L P WHITE.
N Engl J Med, 1959 Apr 16; 260(16). PMID: 13644587
Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1.
Marine Leclerc, Elodie Voilin, +5 authors, Fathia Mami-Chouaib.
Nat Commun, 2019 Jul 28; 10(1). PMID: 31350404    Free PMC article.
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells.
David L Morse, Heather Gray, Claire M Payne, Robert J Gillies.
Mol Cancer Ther, 2005 Oct 18; 4(10). PMID: 16227398
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Jason Madore, Ricardo E Vilain, +9 authors, Richard A Scolyer.
Pigment Cell Melanoma Res, 2014 Dec 06; 28(3). PMID: 25477049
Highly Cited.
Tanning and increased nevus development in very-light-skinned children without red hair.
Jenny Aalborg, Joseph G Morelli, +5 authors, Lori A Crane.
Arch Dermatol, 2009 Sep 23; 145(9). PMID: 19770437    Free PMC article.
PD-1 and PD-1 ligands: from discovery to clinical application.
Taku Okazaki, Tasuku Honjo.
Int Immunol, 2007 Jul 04; 19(7). PMID: 17606980
Highly Cited. Review.
Inhibition of mutated, activated BRAF in metastatic melanoma.
Keith T Flaherty, Igor Puzanov, +8 authors, Paul B Chapman.
N Engl J Med, 2010 Sep 08; 363(9). PMID: 20818844    Free PMC article.
Highly Cited.
Immunologic aspects of tumor induction by ultraviolet radiation.
M L Kripke, M S Fisher.
Natl Cancer Inst Monogr, 1978 Dec 01; (50). PMID: 753974
Chemotherapeutic approaches for targeting cell death pathways.
M Stacey Ricci, Wei-Xing Zong.
Oncologist, 2006 Apr 15; 11(4). PMID: 16614230    Free PMC article.
Review.
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
S A Rosenberg, B S Packard, +7 authors, C A Seipp.
N Engl J Med, 1988 Dec 22; 319(25). PMID: 3264384
Highly Cited.
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation.
Hazem E Ghoneim, Yiping Fan, +8 authors, Ben Youngblood.
Cell, 2017 Jun 27; 170(1). PMID: 28648661    Free PMC article.
Highly Cited.
Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade.
Christopher A Natale, Jinyang Li, +4 authors, Todd W Ridky.
Elife, 2018 Jan 18; 7. PMID: 29336307    Free PMC article.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E A Tivol, F Borriello, +3 authors, A H Sharpe.
Immunity, 1995 Nov 01; 3(5). PMID: 7584144
Highly Cited.
Mutations in GNA11 in uveal melanoma.
Catherine D Van Raamsdonk, Klaus G Griewank, +17 authors, Boris C Bastian.
N Engl J Med, 2010 Nov 19; 363(23). PMID: 21083380    Free PMC article.
Highly Cited.
The ABCDEF Rule: Combining the "ABCDE Rule" and the "Ugly Duckling Sign" in an Effort to Improve Patient Self-Screening Examinations.
J Daniel Jensen, Boni E Elewski.
J Clin Aesthet Dermatol, 2015 Mar 06; 8(2). PMID: 25741397    Free PMC article.
Tumor-infiltrating regulatory T cells: origins and features.
Guoping Deng.
Am J Clin Exp Immunol, 2018 Dec 01; 7(5). PMID: 30498624    Free PMC article.
Review.
Surgery for distant melanoma metastasis.
Anna M Leung, Danielle M Hari, Donald L Morton.
Cancer J, 2012 Mar 29; 18(2). PMID: 22453019    Free PMC article.
Review.
Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells.
Christian P Gray, Paolo Arosio, Peter Hersey.
Blood, 2002 Apr 20; 99(9). PMID: 11964300
Genetics of skin color variation in Europeans: genome-wide association studies with functional follow-up.
Fan Liu, Mijke Visser, +23 authors, Manfred Kayser.
Hum Genet, 2015 May 13; 134(8). PMID: 25963972    Free PMC article.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Keith T Flaherty, Caroline Robert, +23 authors, METRIC Study Group.
N Engl J Med, 2012 Jun 06; 367(2). PMID: 22663011
Highly Cited.
Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.
Sabran J Masoud, Janice B Hu, +2 authors, Paul J Mosca.
Ann Surg Oncol, 2019 Aug 16; 26(13). PMID: 31414290
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Ralf Gutzmer, Daniil Stroyakovskiy, +14 authors, Paolo A Ascierto.
Lancet, 2020 Jun 15; 395(10240). PMID: 32534646
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
P S Linsley, J L Greene, +3 authors, R Peach.
Immunity, 1994 Dec 01; 1(9). PMID: 7534620
Highly Cited.
Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.
Yarí E Marín, Jin Namkoong, +4 authors, Suzie Chen.
Cell Signal, 2005 Nov 25; 18(8). PMID: 16305822
Genotyping of mucosal melanoma.
Lu Si, Xuan Wang, Jun Guo.
Chin Clin Oncol, 2015 Apr 07; 3(3). PMID: 25841460
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
Wenjuan Dong, Xiaojin Wu, +8 authors, Jianhua Yu.
Cancer Discov, 2019 Jul 26; 9(10). PMID: 31340937    Free PMC article.
Highly Cited.
Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg.
Cell, 2011 Mar 08; 144(5). PMID: 21376230
Highly Cited. Review.
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
Yoshiko Iwai, Seigo Terawaki, Tasuku Honjo.
Int Immunol, 2004 Dec 22; 17(2). PMID: 15611321
Highly Cited.
Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.
T Mäkitie, P Summanen, A Tarkkanen, T Kivelä.
Invest Ophthalmol Vis Sci, 2001 May 31; 42(7). PMID: 11381040
PD1 signal transduction pathways in T cells.
Hugo Arasanz, Maria Gato-Cañas, +4 authors, David Escors.
Oncotarget, 2017 Sep 09; 8(31). PMID: 28881701    Free PMC article.
Highly Cited. Review.
Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation.
Isabela Alcázar, Miriam Marqués, +4 authors, Domingo F Barber.
J Exp Med, 2007 Nov 14; 204(12). PMID: 17998387    Free PMC article.
MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project.
Elena Tagliabue, Sara Gandini, +15 authors, Sara Raimondi.
Cancer Manag Res, 2018 May 26; 10. PMID: 29795986    Free PMC article.
Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE).
D Ford, J M Bliss, +7 authors, A Osterlind.
Int J Cancer, 1995 Aug 09; 62(4). PMID: 7635561
Eumelanin and pheomelanin concentrations in human epidermis before and after UVB irradiation.
Alison Hennessy, Carol Oh, +3 authors, Jonathan Rees.
Pigment Cell Res, 2005 May 17; 18(3). PMID: 15892719
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.
Nikolaos Patsoukis, Kankana Bardhan, +9 authors, Vassiliki A Boussiotis.
Nat Commun, 2015 Mar 27; 6. PMID: 25809635    Free PMC article.
Highly Cited.
TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, +9 authors, Rajiv Kumar.
Science, 2013 Jan 26; 339(6122). PMID: 23348503
Highly Cited.
Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease.
M A Alexander, J Bennicelli, D Guerry.
J Immunol, 1989 Jun 01; 142(11). PMID: 2469732
The role of IL-4, IL-10, and TNF-alpha in the immune suppression induced by ultraviolet radiation.
J M Rivas, S E Ullrich.
J Leukoc Biol, 1994 Dec 01; 56(6). PMID: 7996051
Pheomelanin as well as eumelanin is present in human epidermis.
A J Thody, E M Higgins, +3 authors, J M Marks.
J Invest Dermatol, 1991 Aug 01; 97(2). PMID: 2071942
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis.
Nancy Rodig, Timothy Ryan, +8 authors, Gordon J Freeman.
Eur J Immunol, 2003 Oct 28; 33(11). PMID: 14579280
Highly Cited.
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.
Wendy K Nevala, Celine M Vachon, +4 authors, Melanoma Study Group of the Mayo Clinic Cancer Center.
Clin Cancer Res, 2009 Feb 26; 15(6). PMID: 19240164    Free PMC article.
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Katjana Klages, Christian T Mayer, +7 authors, Tim Sparwasser.
Cancer Res, 2010 Oct 07; 70(20). PMID: 20924102
Highly Cited.
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
Benjamin Weide, Alexander Martens, +10 authors, Graham Pawelec.
Clin Cancer Res, 2013 Dec 11; 20(6). PMID: 24323899
Highly Cited.
Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis.
Bin Hou, Yao Tang, +2 authors, Dongmin Chang.
Dis Markers, 2019 Mar 20; 2019. PMID: 30886654    Free PMC article.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.
L Zuo, J Weger, +5 authors, N C Dracopoli.
Nat Genet, 1996 Jan 01; 12(1). PMID: 8528263
Highly Cited.
CD28, CTLA-4 and their ligands: who does what and to whom?
D M Sansom.
Immunology, 2000 Sep 30; 101(2). PMID: 11012769    Free PMC article.
Review.
UV radiation-induced immunosuppression and skin cancer.
Richard D Granstein, Mary S Matsui.
Cutis, 2004 Dec 18; 74(5 Suppl). PMID: 15603215
Review.
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Hyun Tae Lee, Sang Hyung Lee, Yong-Seok Heo.
Molecules, 2019 Mar 29; 24(6). PMID: 30917623    Free PMC article.
Review.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Benjamin Weide, Alexander Martens, +24 authors, Jedd D Wolchok.
Clin Cancer Res, 2016 Nov 01; 22(22). PMID: 27185375    Free PMC article.
Highly Cited.
Mucosal Melanoma: New Insights and Therapeutic Options for a Unique and Aggressive Disease.
Benjamin A Lerner, Latoya A Stewart, David P Horowitz, Richard D Carvajal.
Oncology (Williston Park), 2017 Nov 28; 31(11). PMID: 29179253
Review.
Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma.
Raj Shah, Simar J Singh, +2 authors, Suzie Chen.
Cancer Res, 2019 Apr 17; 79(8). PMID: 30987979    Free PMC article.
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
Curtis A Clark, Harshita B Gupta, +14 authors, Tyler J Curiel.
Cancer Res, 2016 Sep 28; 76(23). PMID: 27671674    Free PMC article.
Highly Cited.
Development of early melanocytic lesions in transgenic mice predisposed to melanoma.
H Zhu, K Reuhl, +3 authors, S Chen.
Pigment Cell Res, 2000 Jul 08; 13(3). PMID: 10885674
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
D J Hicklin, Z Wang, +3 authors, S Ferrone.
J Clin Invest, 1998 Jun 24; 101(12). PMID: 9637706    Free PMC article.
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.
Belal Chaudhary, Eyad Elkord.
Vaccines (Basel), 2016 Aug 12; 4(3). PMID: 27509527    Free PMC article.
Highly Cited. Review.
Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism.
Kunitoshi Chiba, Franziska K Lorbeer, +7 authors, Dirk Hockemeyer.
Science, 2017 Aug 19; 357(6358). PMID: 28818973    Free PMC article.
Highly Cited.
Tumor-infiltrating lymphocytes in melanoma.
Sylvia Lee, Kim Margolin.
Curr Oncol Rep, 2012 Aug 11; 14(5). PMID: 22878966    Free PMC article.
Review.
Ultraviolet radiation-induced immunosuppression and its relevance for skin carcinogenesis.
Prue H Hart, Mary Norval.
Photochem Photobiol Sci, 2017 Nov 15; 17(12). PMID: 29136080
Review.
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.
Alessandra Mazzoni, Vincenzo Bronte, +5 authors, David M Segal.
J Immunol, 2002 Jan 05; 168(2). PMID: 11777962
Highly Cited.
Transient T cell depletion causes regression of melanoma metastases.
Mary Ann Rasku, Amy L Clem, +8 authors, Jason Chesney.
J Transl Med, 2008 Mar 13; 6. PMID: 18334033    Free PMC article.
Plasticity of myeloid-derived suppressor cells in cancer.
Evgenii Tcyganov, Jerome Mastio, Eric Chen, Dmitry I Gabrilovich.
Curr Opin Immunol, 2018 Mar 17; 51. PMID: 29547768    Free PMC article.
Highly Cited. Review.
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, +3 authors, Nagahiro Minato.
Proc Natl Acad Sci U S A, 2002 Sep 10; 99(19). PMID: 12218188    Free PMC article.
Highly Cited.
Whole body irradiation; radiobiology or medicine?
R H MOLE.
Br J Radiol, 1953 May 01; 26(305). PMID: 13042090
Highly Cited.
Cutaneous melanoma in women.
Mi Ryung Roh, Philip Eliades, +2 authors, Hensin Tsao.
Int J Womens Dermatol, 2017 May 12; 3(1 Suppl). PMID: 28492033    Free PMC article.
Review.
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
Nikolaos Patsoukis, Lequn Li, +2 authors, Vassiliki A Boussiotis.
Mol Cell Biol, 2013 Jun 05; 33(16). PMID: 23732914    Free PMC article.
Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner.
Peiwen Chen, Yujie Huang, +5 authors, Yongzhang Luo.
Clin Cancer Res, 2011 Oct 14; 17(23). PMID: 21994414
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.
H Nishimura, T Honjo.
Trends Immunol, 2001 Apr 27; 22(5). PMID: 11323285
Highly Cited.
High frequency of BRAF mutations in nevi.
Pamela M Pollock, Ursula L Harper, +15 authors, Paul S Meltzer.
Nat Genet, 2002 Nov 26; 33(1). PMID: 12447372
Highly Cited.
Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization.
Eleni Vergadi, Eleftheria Ieronymaki, +2 authors, Christos Tsatsanis.
J Immunol, 2017 Jan 25; 198(3). PMID: 28115590
Highly Cited. Review.
Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
N Soufir, M F Avril, +6 authors, B Bressac-de Paillerets.
Hum Mol Genet, 1998 Mar 21; 7(2). PMID: 9425228
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
Janis M Taube, Robert A Anders, +8 authors, Lieping Chen.
Sci Transl Med, 2012 Mar 31; 4(127). PMID: 22461641    Free PMC article.
Highly Cited.
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.
Tricia R Cottrell, Janis M Taube.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360727    Free PMC article.
Review.
Antigen-specific induced T regulatory cells impair dendritic cell function via an IL-10/MARCH1-dependent mechanism.
Gouri Chattopadhyay, Ethan M Shevach.
J Immunol, 2013 Nov 13; 191(12). PMID: 24218453    Free PMC article.
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
Martin Lauss, Marco Donia, +10 authors, Göran Jönsson.
Nat Commun, 2017 Nov 25; 8(1). PMID: 29170503    Free PMC article.
Highly Cited.
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
David Liu, Bastian Schilling, +33 authors, Dirk Schadendorf.
Nat Med, 2019 Dec 04; 25(12). PMID: 31792460    Free PMC article.
Highly Cited.
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.
John F Thompson, Seng-Jaw Soong, +17 authors, Vernon K Sondak.
J Clin Oncol, 2011 Apr 27; 29(16). PMID: 21519009    Free PMC article.
Differential binding properties of B7-H1 and B7-DC to programmed death-1.
Pornpan Youngnak, Yuko Kozono, +8 authors, Miyuki Azuma.
Biochem Biophys Res Commun, 2003 Aug 02; 307(3). PMID: 12893276
Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.
Jared Klarquist, Kristen Tobin, +9 authors, I Caroline Le Poole.
Cancer Res, 2016 Nov 03; 76(21). PMID: 27634754    Free PMC article.
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
Mojgan Ahmadzadeh, Laura A Johnson, +4 authors, Steven A Rosenberg.
Blood, 2009 May 09; 114(8). PMID: 19423728    Free PMC article.
Highly Cited.
B70 antigen is a second ligand for CTLA-4 and CD28.
M Azuma, D Ito, +4 authors, C Somoza.
Nature, 1993 Nov 04; 366(6450). PMID: 7694153
Highly Cited.
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.
Rossana Tallerico, Costanza M Cristiani, +21 authors, Ennio Carbone.
Oncoimmunology, 2017 Mar 28; 6(2). PMID: 28344869    Free PMC article.
A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation.
Anders Molven, Magne B Grimstvedt, +4 authors, Lars A Akslen.
Genes Chromosomes Cancer, 2005 May 10; 44(1). PMID: 15880589
Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
E Jäger, M Ringhoffer, +3 authors, A Knuth.
Int J Cancer, 1996 May 16; 66(4). PMID: 8635862
Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006.
Xiao-Cheng Wu, Melody J Eide, +10 authors, Julian Kim.
J Am Acad Dermatol, 2011 Nov 02; 65(5 Suppl 1). PMID: 22018064
Superior survival of young women with malignant melanoma.
M M Kemeny, E Busch, A K Stewart, H R Menck.
Am J Surg, 1998 Jun 30; 175(6). PMID: 9645769
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.
Peter Johansson, Lauren G Aoude, +16 authors, Nicholas K Hayward.
Oncotarget, 2015 Dec 20; 7(4). PMID: 26683228    Free PMC article.
Highly Cited.
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Xiaofeng Jiang, Jun Zhou, +2 authors, F Stephen Hodi.
Clin Cancer Res, 2012 Oct 26; 19(3). PMID: 23095323
Highly Cited.
Role of LAG-3 in regulatory T cells.
Ching-Tai Huang, Creg J Workman, +11 authors, Dario A A Vignali.
Immunity, 2004 Oct 16; 21(4). PMID: 15485628
Highly Cited.
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer.
Asis Palazón, Julián Aragonés, +2 authors, Ignacio Melero.
Clin Cancer Res, 2011 Dec 30; 18(5). PMID: 22205687
Review.
The association between host susceptibility factors and uveal melanoma: a meta-analysis.
Ezekiel Weis, Chirag P Shah, +2 authors, Carol L Shields.
Arch Ophthalmol, 2006 Jan 13; 124(1). PMID: 16401785
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Carole Achard, Abera Surendran, +3 authors, Carolina S Ilkow.
EBioMedicine, 2018 May 05; 31. PMID: 29724655    Free PMC article.
Review.
Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.
Trine O Jensen, Henrik Schmidt, +5 authors, Torben Steiniche.
J Clin Oncol, 2009 Jun 17; 27(20). PMID: 19528371
Combination Immunotherapy Development in Melanoma.
Alexander M M Eggermont, Marka Crittenden, Jennifer Wargo.
Am Soc Clin Oncol Educ Book, 2018 Sep 21; 38. PMID: 30231333
Review.
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Janis M Taube, Alison Klein, +7 authors, Robert A Anders.
Clin Cancer Res, 2014 Apr 10; 20(19). PMID: 24714771    Free PMC article.
Highly Cited.
Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
Ki Rang Moon, Yoo Duk Choi, +5 authors, Sook Jung Yun.
J Invest Dermatol, 2017 Dec 02; 138(4). PMID: 29191620
Functional effects of GRM1 suppression in human melanoma cells.
Janet Wangari-Talbot, Brian A Wall, James S Goydos, Suzie Chen.
Mol Cancer Res, 2012 Jul 17; 10(11). PMID: 22798429    Free PMC article.
Human skin responses to UV radiation: pigment in the upper epidermis protects against DNA damage in the lower epidermis and facilitates apoptosis.
Yuji Yamaguchi, Kaoruko Takahashi, +6 authors, Vincent J Hearing.
FASEB J, 2006 Jun 24; 20(9). PMID: 16793869
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.
Roy Rabbie, Peter Ferguson, +2 authors, Carla D Robles-Espinoza.
J Pathol, 2018 Dec 05; 247(5). PMID: 30511391    Free PMC article.
Review.
Exosomes released by metabotropic glutamate receptor 1 (GRM1) expressing melanoma cells increase cell migration and invasiveness.
Allison L Isola, Kevinn Eddy, +2 authors, Suzie Chen.
Oncotarget, 2018 Feb 09; 9(1). PMID: 29416686    Free PMC article.
Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988-93.
R D Cress, E A Holly.
Cancer Causes Control, 1997 Mar 01; 8(2). PMID: 9134249
M1 Means Kill; M2 Means Heal.
Klaus Ley.
J Immunol, 2017 Sep 20; 199(7). PMID: 28923980
Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and meta-analysis.
Jing Li, Jian Gu.
J Clin Pharm Ther, 2019 Jan 30; 44(3). PMID: 30693536
Systematic Review.
Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis.
Chirag P Shah, Ezekiel Weis, +2 authors, Carol L Shields.
Ophthalmology, 2005 Jul 30; 112(9). PMID: 16051363
Myeloid-derived suppressor cells in malignant melanoma.
Viktor Umansky, Alexandra Sevko, Christoffer Gebhardt, Jochen Utikal.
J Dtsch Dermatol Ges, 2014 Sep 30; 12(11). PMID: 25263083
Review.
Myeloid-derived suppressor cells as regulators of the immune system.
Dmitry I Gabrilovich, Srinivas Nagaraj.
Nat Rev Immunol, 2009 Feb 07; 9(3). PMID: 19197294    Free PMC article.
Highly Cited. Review.
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
J Guo, R D Carvajal, +18 authors, F S Hodi.
Ann Oncol, 2017 Mar 23; 28(6). PMID: 28327988    Free PMC article.
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Christiane Meyer, Alexandra Sevko, +8 authors, Viktor Umansky.
Proc Natl Acad Sci U S A, 2011 Oct 05; 108(41). PMID: 21969559    Free PMC article.
Highly Cited.
Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2020 Jan 09; 70(1). PMID: 31912902
Highly Cited.
Regulatory T Cells in Melanoma Revisited by a Computational Clustering of FOXP3+ T Cell Subpopulations.
Hiroko Fujii, Julie Josse, +3 authors, Masahiro Ono.
J Immunol, 2016 Feb 13; 196(6). PMID: 26864030    Free PMC article.
Somatic activation of KIT in distinct subtypes of melanoma.
John A Curtin, Klaus Busam, Daniel Pinkel, Boris C Bastian.
J Clin Oncol, 2006 Aug 16; 24(26). PMID: 16908931
Highly Cited.
A clinicopathologic analysis of 177 acral melanomas in Koreans: relevance of spreading pattern and physical stress.
Ho Joo Jung, Sun-Seog Kweon, +2 authors, Sook Jung Yun.
JAMA Dermatol, 2013 Sep 27; 149(11). PMID: 24067997
Foxp3+ T Regulatory Cells: Still Many Unanswered Questions-A Perspective After 20 Years of Study.
Ethan M Shevach.
Front Immunol, 2018 Jun 06; 9. PMID: 29868011    Free PMC article.
Highly Cited. Review.
CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer.
Christina Friese, Katja Harbst, +7 authors, Özcan Met.
Sci Rep, 2020 Mar 05; 10(1). PMID: 32127601    Free PMC article.
Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Jahan S Khalili, Xiaoxing Yu, +5 authors, Scott E Woodman.
Clin Cancer Res, 2012 Jun 27; 18(16). PMID: 22733540    Free PMC article.
Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1.
Christina M Maher, Jeffrey D Thomas, +4 authors, Felix J Kim.
Mol Cancer Res, 2017 Nov 10; 16(2). PMID: 29117944
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Alexander Thiem, Sonja Hesbacher, +7 authors, David Schrama.
J Exp Clin Cancer Res, 2019 Sep 12; 38(1). PMID: 31506076    Free PMC article.
Update on immunotherapy in melanoma.
Jamie Green, Charlotte Ariyan.
Surg Oncol Clin N Am, 2015 Mar 15; 24(2). PMID: 25769716
Review.
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.
Yochai Wolf, Osnat Bartok, +26 authors, Yardena Samuels.
Cell, 2019 Sep 17; 179(1). PMID: 31522890    Free PMC article.
Highly Cited.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, +16 authors, T Honjo.
J Exp Med, 2000 Oct 04; 192(7). PMID: 11015443    Free PMC article.
Highly Cited.
Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes.
E Apolloni, V Bronte, +5 authors, P Zanovello.
J Immunol, 2000 Dec 20; 165(12). PMID: 11120790
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Maria Pia Pistillo, Vincenzo Fontana, +26 authors, Italian Melanoma Intergroup (IMI).
Cancer Immunol Immunother, 2018 Oct 13; 68(1). PMID: 30311027
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Bradley C Carthon, Jedd D Wolchok, +8 authors, Padmanee Sharma.
Clin Cancer Res, 2010 May 13; 16(10). PMID: 20460488    Free PMC article.
Highly Cited.
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H Nishimura, M Nose, +2 authors, T Honjo.
Immunity, 1999 Sep 15; 11(2). PMID: 10485649
Highly Cited.
Myeloid cells.
Hiroshi Kawamoto, Nagahiro Minato.
Int J Biochem Cell Biol, 2004 May 19; 36(8). PMID: 15147715
Review.
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.
Anna-Maria Georgoudaki, Kajsa E Prokopec, +14 authors, Mikael C I Karlsson.
Cell Rep, 2016 May 24; 15(9). PMID: 27210762
Highly Cited.
Melanomas of the palm, sole, and nailbed: a clinicopathologic study.
C E Feibleman, H Stoll, J C Maize.
Cancer, 1980 Dec 01; 46(11). PMID: 7438021
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Adil I Daud, Jedd D Wolchok, +21 authors, Omid Hamid.
J Clin Oncol, 2016 Nov 20; 34(34). PMID: 27863197    Free PMC article.
Highly Cited.
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.
Mengnan He, Yan Chai, +6 authors, George F Gao.
Oncotarget, 2017 Oct 06; 8(40). PMID: 28978021    Free PMC article.
Biochemical signaling of PD-1 on T cells and its functional implications.
Vassiliki A Boussiotis, Pranam Chatterjee, Lequn Li.
Cancer J, 2014 Aug 08; 20(4). PMID: 25098287    Free PMC article.
Review.
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.
Kiavash Movahedi, Damya Laoui, +8 authors, Jo A Van Ginderachter.
Cancer Res, 2010 Jun 24; 70(14). PMID: 20570887
Highly Cited.
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood.
Katrin Klocke, Shimon Sakaguchi, Rikard Holmdahl, Kajsa Wing.
Proc Natl Acad Sci U S A, 2016 Apr 14; 113(17). PMID: 27071130    Free PMC article.
Highly Cited.
Suppression of antigen presentation by IL-10.
Sharad K Mittal, Paul A Roche.
Curr Opin Immunol, 2015 Jan 20; 34. PMID: 25597442    Free PMC article.
Highly Cited. Review.
Primary mucosal melanomas: a comprehensive review.
Marija Mihajlovic, Slobodan Vlajkovic, Predrag Jovanovic, Vladisav Stefanovic.
Int J Clin Exp Pathol, 2012 Oct 17; 5(8). PMID: 23071856    Free PMC article.
Review.
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, +21 authors, Garrett M Frampton.
Genome Med, 2017 Apr 20; 9(1). PMID: 28420421    Free PMC article.
Highly Cited.
VISTA is an immune checkpoint molecule for human T cells.
J Louise Lines, Eirini Pantazi, +8 authors, Randolph Noelle.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691993    Free PMC article.
Highly Cited.
Sex steroids regulate skin pigmentation through nonclassical membrane-bound receptors.
Christopher A Natale, Elizabeth K Duperret, +6 authors, Todd W Ridky.
Elife, 2016 Apr 27; 5. PMID: 27115344    Free PMC article.
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.
Damya Laoui, Eva Van Overmeire, +14 authors, Jo A Van Ginderachter.
Cancer Res, 2013 Nov 14; 74(1). PMID: 24220244
Highly Cited.
Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.
Winnie S Liang, William Hendricks, +23 authors, Jeffrey Trent.
Genome Res, 2017 Apr 05; 27(4). PMID: 28373299    Free PMC article.
Predictors of mucosal melanoma survival in a population-based setting.
Lisa Altieri, Megan Eguchi, David H Peng, Myles Cockburn.
J Am Acad Dermatol, 2018 Oct 09; 81(1). PMID: 30296542    Free PMC article.
Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
J L Greene, G M Leytze, +4 authors, P S Linsley.
J Biol Chem, 1996 Oct 25; 271(43). PMID: 8900156
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Jun Zhou, Kathleen M Mahoney, +13 authors, F Stephen Hodi.
Cancer Immunol Res, 2017 May 20; 5(6). PMID: 28522460    Free PMC article.
Highly Cited.
Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy.
Richard Tyrell, Camila Antia, Sharon Stanley, Gary B Deutsch.
Melanoma Manag, 2017 Mar 01; 4(1). PMID: 30190905    Free PMC article.
Review.
Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.
E R Kearney, T L Walunas, +4 authors, M K Jenkins.
J Immunol, 1995 Aug 01; 155(3). PMID: 7543510
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.
Catherine D Van Raamsdonk, Vladimir Bezrookove, +6 authors, Boris C Bastian.
Nature, 2008 Dec 17; 457(7229). PMID: 19078957    Free PMC article.
Highly Cited.
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
Edward Cha, Mark Klinger, +4 authors, Lawrence Fong.
Sci Transl Med, 2014 May 30; 6(238). PMID: 24871131    Free PMC article.
Highly Cited.
Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.
Xiaodong Feng, Maria Sol Degese, +9 authors, J Silvio Gutkind.
Cancer Cell, 2014 Jun 03; 25(6). PMID: 24882515    Free PMC article.
Highly Cited.
Double agents: genes with both oncogenic and tumor-suppressor functions.
Libing Shen, Qili Shi, Wenyuan Wang.
Oncogenesis, 2018 Mar 16; 7(3). PMID: 29540752    Free PMC article.
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, +17 authors, Keith T Flaherty.
Lancet Oncol, 2018 Sep 17; 19(10). PMID: 30219628
Highly Cited.
Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation.
Stanley Ching-Cheng Huang, Amber M Smith, +4 authors, Edward J Pearce.
Immunity, 2016 Oct 21; 45(4). PMID: 27760338    Free PMC article.
Highly Cited.
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Gang Chen, Alexander C Huang, +36 authors, Wei Guo.
Nature, 2018 Aug 10; 560(7718). PMID: 30089911    Free PMC article.
Highly Cited.
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer.
Anders Handrup Kverneland, Magnus Pedersen, +11 authors, Inge Marie Svane.
Oncotarget, 2020 Jun 18; 11(22). PMID: 32547707    Free PMC article.
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
P Waterhouse, J M Penninger, +6 authors, T W Mak.
Science, 1995 Nov 10; 270(5238). PMID: 7481803
Highly Cited.
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
Deborah Kuk, Alexander N Shoushtari, +11 authors, Michael A Postow.
Oncologist, 2016 Jun 12; 21(7). PMID: 27286787    Free PMC article.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, +26 authors, BRIM-3 Study Group.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639808    Free PMC article.
Highly Cited.
Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells.
Haley Ataera, Evelyn Hyde, +2 authors, Franca Ronchese.
PLoS One, 2011 Mar 11; 6(3). PMID: 21390236    Free PMC article.
Sex-associated molecular differences for cancer immunotherapy.
Youqiong Ye, Ying Jing, +4 authors, Leng Han.
Nat Commun, 2020 Apr 15; 11(1). PMID: 32286310    Free PMC article.
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.
W H Clark, D E Elder, +3 authors, M Van Horn.
Hum Pathol, 1984 Dec 01; 15(12). PMID: 6500548
Highly Cited.
Mechanisms of UV-induced immunosuppression.
Thomas Schwarz.
Keio J Med, 2006 Feb 03; 54(4). PMID: 16452825
Review.
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Laura A Johnson, Richard A Morgan, +22 authors, Steven A Rosenberg.
Blood, 2009 May 20; 114(3). PMID: 19451549    Free PMC article.
Highly Cited.
Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types.
Angela M Magnuson, Evgeny Kiner, +8 authors, Christophe Benoist.
Proc Natl Acad Sci U S A, 2018 Oct 24; 115(45). PMID: 30348759    Free PMC article.
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF.
Michael Quigley, Florencia Pereyra, +23 authors, W Nicholas Haining.
Nat Med, 2010 Oct 05; 16(10). PMID: 20890291    Free PMC article.
Highly Cited.
Early detection of malignant melanoma: the role of physician examination and self-examination of the skin.
R J Friedman, D S Rigel, A W Kopf.
CA Cancer J Clin, 1985 May 01; 35(3). PMID: 3921200
Highly Cited.
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction.
Elisabetta Contardi, Giulio L Palmisano, +15 authors, Maria Pia Pistillo.
Int J Cancer, 2005 May 25; 117(4). PMID: 15912538
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
Tyler J Curiel, Shuang Wei, +19 authors, Weiping Zou.
Nat Med, 2003 Apr 22; 9(5). PMID: 12704383
Highly Cited.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice.
Sharmilla Devi Jayasingam, Marimuthu Citartan, +3 authors, Ewe Seng Ch'ng.
Front Oncol, 2020 Feb 11; 9. PMID: 32039007    Free PMC article.
Review.
Development of heritable melanoma in transgenic mice.
H Zhu, K Reuhl, +4 authors, S Chen.
J Invest Dermatol, 1998 Mar 20; 110(3). PMID: 9506443
Natural variation of macrophage activation as disease-relevant phenotype predictive of inflammation and cancer survival.
Konrad Buscher, Erik Ehinger, +7 authors, Klaus Ley.
Nat Commun, 2017 Jul 25; 8. PMID: 28737175    Free PMC article.
Chemotherapy induces tumor clearance independent of apoptosis.
Jennifer L Guerriero, Dara Ditsworth, +3 authors, Wei-Xing Zong.
Cancer Res, 2008 Dec 03; 68(23). PMID: 19047135    Free PMC article.
The melanosome: a distinctive subcellular particle of mammalian melanocytes and the site of melanogenesis.
M SEIJI, T B FITZPATRICK, M S BIRBECK.
J Invest Dermatol, 1961 Apr 01; 36. PMID: 13749804
Development of cutaneous amelanotic melanoma in the absence of a functional tyrosinase.
K A Cohen-Solal, K R Reuhl, +2 authors, S Chen.
Pigment Cell Res, 2002 Jan 05; 14(6). PMID: 11775059
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer.
Weiting Qin, Lipeng Hu, +4 authors, Xu Wang.
Front Immunol, 2019 Oct 23; 10. PMID: 31636634    Free PMC article.
Highly Cited. Review.
Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria.
Naheed R Abbasi, Helen M Shaw, +5 authors, David Polsky.
JAMA, 2004 Dec 09; 292(22). PMID: 15585738
Review.
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Gerald S Falchook, Georgina V Long, +14 authors, Richard F Kefford.
Lancet, 2012 May 23; 379(9829). PMID: 22608338    Free PMC article.
Highly Cited.
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.
Joseph F Grosso, Cristin C Kelleher, +10 authors, Charles G Drake.
J Clin Invest, 2007 Oct 13; 117(11). PMID: 17932562    Free PMC article.
Highly Cited.
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
C A Chambers, M S Kuhns, J G Egen, J P Allison.
Annu Rev Immunol, 2001 Mar 13; 19. PMID: 11244047
Highly Cited. Review.
Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
Maartje W Rohaan, Joost H van den Berg, Pia Kvistborg, John B A G Haanen.
J Immunother Cancer, 2018 Oct 05; 6(1). PMID: 30285902    Free PMC article.
Review.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, +19 authors, F Stephen Hodi.
Nature, 2014 Nov 28; 515(7528). PMID: 25428504    Free PMC article.
Highly Cited.
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.
T Okazaki, A Maeda, +2 authors, T Honjo.
Proc Natl Acad Sci U S A, 2001 Nov 08; 98(24). PMID: 11698646    Free PMC article.
Highly Cited.
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Paolo A Ascierto, Grant A McArthur, +18 authors, James Larkin.
Lancet Oncol, 2016 Aug 03; 17(9). PMID: 27480103
Highly Cited.
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
Dmitriy Zamarin, Rikke B Holmgaard, +6 authors, James P Allison.
Sci Transl Med, 2014 Mar 07; 6(226). PMID: 24598590    Free PMC article.
Highly Cited.
Melanoma-Derived Exosomal miR-125b-5p Educates Tumor Associated Macrophages (TAMs) by Targeting Lysosomal Acid Lipase A (LIPA).
Dennis Gerloff, Jana Lützkendorf, +4 authors, Cord Sunderkötter.
Cancers (Basel), 2020 Feb 23; 12(2). PMID: 32079286    Free PMC article.
PI3Kγ is a molecular switch that controls immune suppression.
Megan M Kaneda, Karen S Messer, +20 authors, Judith A Varner.
Nature, 2016 Nov 01; 539(7629). PMID: 27642729    Free PMC article.
Highly Cited.
Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α.
Genevieve Hartley, Daniel Regan, Amanda Guth, Steven Dow.
Cancer Immunol Immunother, 2017 Feb 12; 66(4). PMID: 28184968    Free PMC article.
Using Dermoscopy to Identify Melanoma and Improve Diagnostic Discrimination.
G Alden Holmes, Janna M Vassantachart, +3 authors, Sharon E Jacob.
Fed Pract, 2019 Feb 16; 35(Suppl 4). PMID: 30766399    Free PMC article.
Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma.
Christian P Gray, Paolo Arosio, Peter Hersey.
Clin Cancer Res, 2003 Jul 12; 9(7). PMID: 12855630
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy.
Aline Pfefferle, Nicholas D Huntington.
Cancers (Basel), 2020 Mar 21; 12(3). PMID: 32192067    Free PMC article.
Review.
MYC regulates the antitumor immune response through CD47 and PD-L1.
Stephanie C Casey, Ling Tong, +8 authors, Dean W Felsher.
Science, 2016 Mar 12; 352(6282). PMID: 26966191    Free PMC article.
Highly Cited.
Glutamatergic signaling in cellular transformation.
Jessica L F Teh, Suzie Chen.
Pigment Cell Melanoma Res, 2012 Jan 26; 25(3). PMID: 22273393
Review.
Loci associated with skin pigmentation identified in African populations.
Nicholas G Crawford, Derek E Kelly, +45 authors, Sarah A Tishkoff.
Science, 2017 Oct 14; 358(6365). PMID: 29025994    Free PMC article.
Highly Cited.
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.
Pamela M Pollock, Karine Cohen-Solal, +27 authors, Suzie Chen.
Nat Genet, 2003 Apr 22; 34(1). PMID: 12704387
Highly Cited.
Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Jessica R Ingram, Olga S Blomberg, +15 authors, Michael Dougan.
Proc Natl Acad Sci U S A, 2018 Mar 28; 115(15). PMID: 29581255    Free PMC article.
Highly Cited.
FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma.
Andrea Ladányi, Anita Mohos, +5 authors, József Tímár.
Pathol Oncol Res, 2010 Mar 23; 16(3). PMID: 20306313
Improved overall survival in melanoma with combined dabrafenib and trametinib.
Caroline Robert, Boguslawa Karaszewska, +24 authors, Dirk Schadendorf.
N Engl J Med, 2014 Nov 18; 372(1). PMID: 25399551
Highly Cited.
Ethnic differences among patients with cutaneous melanoma.
Janice N Cormier, Yan Xing, +5 authors, Xianglin L Du.
Arch Intern Med, 2006 Sep 27; 166(17). PMID: 17000949
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O Alsaab, Samaresh Sau, +4 authors, Arun K Iyer.
Front Pharmacol, 2017 Sep 08; 8. PMID: 28878676    Free PMC article.
Highly Cited. Review.
Sun exposure and melanocytic naevi in young Australian children.
S L Harrison, R MacLennan, R Speare, I Wronski.
Lancet, 1994 Dec 03; 344(8936). PMID: 7983952
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Pia Kvistborg, Daisy Philips, +13 authors, Ton N Schumacher.
Sci Transl Med, 2014 Sep 19; 6(254). PMID: 25232180
Highly Cited.
Liver damage related to immune checkpoint inhibitors.
Naoshi Nishida, Masatoshi Kudo.
Hepatol Int, 2019 Jan 05; 13(3). PMID: 30607787
Review.
Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.
Jae Hun Shin, Hyung Bae Park, +8 authors, Kyungho Choi.
Blood, 2012 Apr 28; 119(24). PMID: 22538857
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Alberto Carretero-González, David Lora, +6 authors, Guillermo de Velasco.
Oncotarget, 2018 Mar 02; 9(9). PMID: 29492229    Free PMC article.
AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1).
Seung-Shick Shin, Brian A Wall, James S Goydos, Suzie Chen.
Pigment Cell Melanoma Res, 2009 Oct 22; 23(1). PMID: 19843246    Free PMC article.
Xeroderma Pigmentosum.
Jennifer O Black.
Head Neck Pathol, 2016 Mar 16; 10(2). PMID: 26975629    Free PMC article.
Review.
Molecular genetics of human pigmentation diversity.
Richard A Sturm.
Hum Mol Genet, 2009 Mar 20; 18(R1). PMID: 19297406
Highly Cited. Review.
Detection of M2-macrophages in uveal melanoma and relation with survival.
Inge H G Bronkhorst, Long V Ly, +4 authors, Martine J Jager.
Invest Ophthalmol Vis Sci, 2010 Sep 03; 52(2). PMID: 20811059
Highly pigmented Tg(Grm1) mouse melanoma develops non-pigmented melanoma cells in distant metastases.
Susanne Schiffner, Suzie Chen, Jürgen C Becker, Anja-Katrin Bosserhoff.
Exp Dermatol, 2012 Aug 14; 21(10). PMID: 22882420
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.
Simon J Furney, Samra Turajlic, +9 authors, Richard Marais.
J Pathol, 2013 Apr 27; 230(3). PMID: 23620124
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
Cesar A Corzo, Thomas Condamine, +10 authors, Dmitry I Gabrilovich.
J Exp Med, 2010 Sep 30; 207(11). PMID: 20876310    Free PMC article.
Highly Cited.
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.
Jung-Mao Hsu, Chia-Wei Li, Yun-Ju Lai, Mien-Chie Hung.
Cancer Res, 2018 Nov 18; 78(22). PMID: 30442814    Free PMC article.
Review.
Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
Christopher J Gannon, Dennis L Rousseau, +6 authors, Jeffrey E Gershenwald.
Cancer, 2006 Oct 26; 107(11). PMID: 17063497
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Jonas N Søndergaard, Ramin Nazarian, +16 authors, Antoni Ribas.
J Transl Med, 2010 Apr 22; 8. PMID: 20406486    Free PMC article.
Highly Cited.
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Paolo A Ascierto, David Minor, +17 authors, Uwe Trefzer.
J Clin Oncol, 2013 Aug 07; 31(26). PMID: 23918947
Highly Cited.
GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis.
Xinan Sheng, Yan Kong, +12 authors, Jun Guo.
Eur J Cancer, 2016 Aug 09; 65. PMID: 27498141
PD-1 on dendritic cells impedes innate immunity against bacterial infection.
Sheng Yao, Shengdian Wang, +9 authors, Lieping Chen.
Blood, 2009 Apr 03; 113(23). PMID: 19339692    Free PMC article.
Myeloid-Derived Suppressor Cells.
Dmitry I Gabrilovich.
Cancer Immunol Res, 2017 Jan 06; 5(1). PMID: 28052991    Free PMC article.
Highly Cited. Review.
The effect of misdiagnosis and delay in diagnosis on clinical outcome in melanomas of the foot.
D R Bennett, D Wasson, J D MacArthur, M A McMillen.
J Am Coll Surg, 1994 Sep 01; 179(3). PMID: 8069422
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Ioannis Zerdes, Alexios Matikas, +2 authors, Theodoros Foukakis.
Oncogene, 2018 May 17; 37(34). PMID: 29765155    Free PMC article.
Highly Cited. Review.
The Genetic Evolution of Melanoma from Precursor Lesions.
A Hunter Shain, Iwei Yeh, +11 authors, Boris C Bastian.
N Engl J Med, 2015 Nov 13; 373(20). PMID: 26559571
Highly Cited.
Immunotherapy of melanoma.
John B A G Haanen.
EJC Suppl, 2013 Sep 01; 11(2). PMID: 26217118    Free PMC article.
Review.
Adoptive T cell immunotherapy for cancer.
Karlo Perica, Juan Carlos Varela, Mathias Oelke, Jonathan Schneck.
Rambam Maimonides Med J, 2015 Feb 27; 6(1). PMID: 25717386    Free PMC article.
Review.
The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
Satu Salmi, Hanna Siiskonen, +5 authors, Sanna Pasonen-Seppänen.
Melanoma Res, 2018 Nov 07; 29(3). PMID: 30399061    Free PMC article.
Role of radiotherapy in melanoma management.
Primoz Strojan.
Radiol Oncol, 2010 Mar 01; 44(1). PMID: 22933884    Free PMC article.
IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence.
Eijun Itakura, Rong-Rong Huang, +3 authors, Alistair J Cochran.
Mod Pathol, 2011 Feb 15; 24(6). PMID: 21317876    Free PMC article.
Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.
Manuelle Viguier, Fabrice Lemaître, +6 authors, Laurent Ferradini.
J Immunol, 2004 Jul 09; 173(2). PMID: 15240741
Highly Cited.
Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects.
D D Taylor, C Gerçel-Taylor.
Br J Cancer, 2005 Jan 19; 92(2). PMID: 15655551    Free PMC article.
Highly Cited.
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Julien Fourcade, Zhaojun Sun, +6 authors, Hassane M Zarour.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819923    Free PMC article.
Highly Cited.
Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.
Marco Donia, Rikke Andersen, +6 authors, Inge Marie Svane.
Cancer Res, 2015 Jul 18; 75(18). PMID: 26183926
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Jennifer H Yearley, Christopher Gibson, +10 authors, Terrill McClanahan.
Clin Cancer Res, 2017 Jun 18; 23(12). PMID: 28619999
Highly Cited.
Efficacy of immune checkpoint inhibitors in different types of melanoma.
Ernesto Rossi, Giovanni Schinzari, +13 authors, Giampaolo Tortora.
Hum Vaccin Immunother, 2020 Jul 15; 17(1). PMID: 32663057    Free PMC article.
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors.
Saman Maleki Vareki.
J Immunother Cancer, 2018 Dec 28; 6(1). PMID: 30587233    Free PMC article.
Highly Cited.
Pro-tumor activities of macrophages in the progression of melanoma.
Huafeng Wang, Luhong Yang, +2 authors, Lijuan Zhang.
Hum Vaccin Immunother, 2017 Apr 26; 13(7). PMID: 28441072    Free PMC article.
Review.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2019 Sep 29; 381(16). PMID: 31562797
Highly Cited.
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
Genevieve P Hartley, Lyndah Chow, +2 authors, Steven W Dow.
Cancer Immunol Res, 2018 Jul 18; 6(10). PMID: 30012633
Highly Cited.
First oncolytic virus approved for melanoma immunotherapy.
Jonathan Pol, Guido Kroemer, Lorenzo Galluzzi.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942095    Free PMC article.
Highly Cited.
CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions.
Stefania Laurent, Paolo Carrega, +10 authors, Maria Pia Pistillo.
Hum Immunol, 2010 Jul 24; 71(10). PMID: 20650297
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells.
Marco Tucci, Anna Passarelli, +4 authors, Francesco Silvestris.
Front Oncol, 2019 Nov 22; 9. PMID: 31750245    Free PMC article.
Review.
Coinhibitory Pathways in Immunotherapy for Cancer.
Susanne H Baumeister, Gordon J Freeman, Glenn Dranoff, Arlene H Sharpe.
Annu Rev Immunol, 2016 Mar 02; 34. PMID: 26927206
Highly Cited. Review.
Uveal melanoma: relatively rare but deadly cancer.
S Kaliki, C L Shields.
Eye (Lond), 2016 Dec 03; 31(2). PMID: 27911450    Free PMC article.
Review.
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.
Alisa M Goldstein, May Chan, +37 authors, Melanoma Genetics Consortium (GenoMEL).
Cancer Res, 2006 Oct 19; 66(20). PMID: 17047042
Highly Cited.
STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion.
Sergei Kusmartsev, Dmitry I Gabrilovich.
J Immunol, 2005 Apr 09; 174(8). PMID: 15814715
Highly Cited.
Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
J N Cormier, A Abati, +4 authors, S L Topalian.
J Immunother, 1998 Feb 11; 21(1). PMID: 9456433
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, +21 authors, David Kaufman.
Science, 2018 Oct 13; 362(6411). PMID: 30309915    Free PMC article.
Highly Cited.
Melanoma-Derived Extracellular Vesicles Bear the Potential for the Induction of Antigen-Specific Tolerance.
Markus Düchler, Liliana Czernek, +3 authors, Malgorzata Czyz.
Cells, 2019 Jul 05; 8(7). PMID: 31269655    Free PMC article.
Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma.
Y Ohtani, T Harada, +7 authors, A Aiba.
Oncogene, 2008 Sep 09; 27(57). PMID: 18776920
Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.
Kristin Turza, Lynn T Dengel, +4 authors, Craig L Slingluff.
J Cutan Pathol, 2009 Jul 16; 37(1). PMID: 19602071    Free PMC article.
Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry.
Kai Huang, Ji Fan, Subhasis Misra.
J Surg Res, 2020 Mar 26; 251. PMID: 32208196
Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4.
Xuan Mo, Hanghang Zhang, +7 authors, M Raza Zaidi.
Cancer Res, 2017 Nov 19; 78(2). PMID: 29150430    Free PMC article.
Immunologic parameters of ultraviolet carcinogenesis.
M L Kripke, M S Fisher.
J Natl Cancer Inst, 1976 Jul 01; 57(1). PMID: 1003502
M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles.
Martina C Herwig, Chris Bergstrom, +2 authors, Hans E Grossniklaus.
Exp Eye Res, 2012 Dec 05; 107. PMID: 23206928    Free PMC article.
Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Genevieve J Kaunitz, Tricia R Cottrell, +16 authors, Janis M Taube.
Lab Invest, 2017 Jul 25; 97(9). PMID: 28737763    Free PMC article.
Arginine metabolism in tumor-associated macrophages in cutaneous malignant melanoma: evidence from human and experimental tumors.
Daniela Massi, Chiara Marconi, +6 authors, Lido Calorini.
Hum Pathol, 2007 Jul 21; 38(10). PMID: 17640716
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, +9 authors, F Stephen Hodi.
Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295
Highly Cited.
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.
Jennifer A Lo, David E Fisher.
Science, 2014 Nov 22; 346(6212). PMID: 25414302    Free PMC article.
Highly Cited. Review.
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
J N Cormier, Y M Hijazi, +5 authors, F M Marincola.
Int J Cancer, 1998 Feb 18; 75(4). PMID: 9466650
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
V Gopalakrishnan, C N Spencer, +67 authors, J A Wargo.
Science, 2017 Nov 04; 359(6371). PMID: 29097493    Free PMC article.
Highly Cited.
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.
Mojgan Ahmadzadeh, Aloisio Felipe-Silva, +4 authors, Steven A Rosenberg.
Blood, 2008 Sep 30; 112(13). PMID: 18820132    Free PMC article.
The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway.
David E Elder, Boris C Bastian, +2 authors, Richard A Scolyer.
Arch Pathol Lab Med, 2020 Feb 15; 144(4). PMID: 32057276
Review.
Revealing the genomic heterogeneity of melanoma.
Omar Kabbarah, Lynda Chin.
Cancer Cell, 2005 Dec 13; 8(6). PMID: 16338657
Review.
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes.
Marlana Orloff.
Oncolytic Virother, 2016 Oct 28; 5. PMID: 27785448    Free PMC article.
Review.
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Ayelet Sivan, Leticia Corrales, +9 authors, Thomas F Gajewski.
Science, 2015 Nov 07; 350(6264). PMID: 26541606    Free PMC article.
Highly Cited.
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Ernesto Rossi, Giovanni Schinzari, +11 authors, Giampaolo Tortora.
Cancers (Basel), 2019 Jul 31; 11(8). PMID: 31357439    Free PMC article.
Review.
Guidelines of care for the management of primary cutaneous melanoma.
Susan M Swetter, Hensin Tsao, +13 authors, Toyin Lamina.
J Am Acad Dermatol, 2018 Nov 06; 80(1). PMID: 30392755
Immunologic correlates of the abscopal effect in a patient with melanoma.
Michael A Postow, Margaret K Callahan, +18 authors, Jedd D Wolchok.
N Engl J Med, 2012 Mar 09; 366(10). PMID: 22397654    Free PMC article.
Highly Cited.
An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
Patrick A Ott, Gianpietro Dotti, Cassian Yee, Stephanie L Goff.
Am Soc Clin Oncol Educ Book, 2019 May 18; 39. PMID: 31099621
Review.
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Rituparna Das, Rakesh Verma, +8 authors, Kavita M Dhodapkar.
J Immunol, 2014 Dec 30; 194(3). PMID: 25539810    Free PMC article.
Highly Cited.
The reciprocal relationship between melanization and tyrosinase activity in melanosomes (melanin granules).
M SEIJI, T B FITZPATRICK.
J Biochem, 1961 Jun 01; 49. PMID: 13749805
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab.
Maria Pia Pistillo, Roberta Carosio, +12 authors, Paola Queirolo.
Clin Immunol, 2020 Apr 29; 215. PMID: 32344017
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
Richard V Parry, Jens M Chemnitz, +6 authors, James L Riley.
Mol Cell Biol, 2005 Oct 18; 25(21). PMID: 16227604    Free PMC article.
Highly Cited.
Strength of immune selection in tumors varies with sex and age.
Andrea Castro, Rachel Marty Pyke, +5 authors, Hannah Carter.
Nat Commun, 2020 Aug 19; 11(1). PMID: 32807809    Free PMC article.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lesley Seymour, Jan Bogaerts, +16 authors, RECIST working group.
Lancet Oncol, 2017 Mar 09; 18(3). PMID: 28271869    Free PMC article.
Highly Cited. Review.
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.
Anshuman Panda, Anil Betigeri, +14 authors, Shridar Ganesan.
JCO Precis Oncol, 2017 Jan 01; 2017. PMID: 29951597    Free PMC article.
Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation.
Seung-Shick Shin, Jin Namkoong, +3 authors, Suzie Chen.
Pigment Cell Melanoma Res, 2008 Apr 26; 21(3). PMID: 18435704    Free PMC article.
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, +10 authors, Lieping Chen.
Nat Med, 2002 Jul 02; 8(8). PMID: 12091876
Highly Cited.
An immune-active tumor microenvironment favors clinical response to ipilimumab.
Rui-Ru Ji, Scott D Chasalow, +9 authors, Vafa Shahabi.
Cancer Immunol Immunother, 2011 Dec 08; 61(7). PMID: 22146893
Highly Cited.
Is the scavenger receptor MARCO a new immune checkpoint?
Mohamed S Arredouani.
Oncoimmunology, 2015 May 06; 3(10). PMID: 25941575    Free PMC article.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, +30 authors, James Larkin.
N Engl J Med, 2017 Sep 12; 377(14). PMID: 28889792    Free PMC article.
Highly Cited.
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Michal J Besser, Ronnie Shapira-Frommer, +17 authors, Jacob Schachter.
Clin Cancer Res, 2010 Apr 22; 16(9). PMID: 20406835
Highly Cited.
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
James Tsai, John T Lee, +35 authors, Gideon Bollag.
Proc Natl Acad Sci U S A, 2008 Feb 22; 105(8). PMID: 18287029    Free PMC article.
Highly Cited.
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.
Jens M Chemnitz, Richard V Parry, +2 authors, James L Riley.
J Immunol, 2004 Jul 09; 173(2). PMID: 15240681
Highly Cited.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, +7 authors, Daniel E Speiser.
Proc Natl Acad Sci U S A, 2015 Apr 29; 112(19). PMID: 25918390    Free PMC article.
Highly Cited.
Regulation of tumor metastasis by myeloid-derived suppressor cells.
Thomas Condamine, Indu Ramachandran, Je-In Youn, Dmitry I Gabrilovich.
Annu Rev Med, 2014 Oct 24; 66. PMID: 25341012    Free PMC article.
Highly Cited. Review.
Origin and characteristics of ultraviolet-B radiation-induced suppressor T lymphocytes.
V K Shreedhar, M W Pride, +2 authors, F M Strickland.
J Immunol, 1998 Aug 01; 161(3). PMID: 9686595
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
Hanne Eknes Puntervoll, Xiaohong R Yang, +30 authors, Anders Molven.
J Med Genet, 2013 Feb 07; 50(4). PMID: 23384855    Free PMC article.
Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer.
Taku Fujimura, Yumi Kambayashi, +2 authors, Setsuya Aiba.
Front Oncol, 2018 Feb 08; 8. PMID: 29410946    Free PMC article.
Review.
Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.
Miriam Alb, Christopher Sie, +3 authors, David Schrama.
Cancer Immunol Immunother, 2012 Jun 08; 61(12). PMID: 22674057    Free PMC article.
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
Chia-Wei Li, Seung-Oe Lim, +21 authors, Mien-Chie Hung.
Nat Commun, 2016 Aug 31; 7. PMID: 27572267    Free PMC article.
Highly Cited.
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.
A Breslow.
Ann Surg, 1970 Nov 01; 172(5). PMID: 5477666    Free PMC article.
Highly Cited.
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Jeffrey E Gershenwald, Richard A Scolyer, +13 authors, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.
CA Cancer J Clin, 2017 Oct 14; 67(6). PMID: 29028110    Free PMC article.
Highly Cited.
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Steven A Rosenberg, James C Yang, +12 authors, Mark E Dudley.
Clin Cancer Res, 2011 Apr 19; 17(13). PMID: 21498393    Free PMC article.
Highly Cited.
The protective role of melanin against UV damage in human skin.
Michaela Brenner, Vincent J Hearing.
Photochem Photobiol, 2008 Apr 26; 84(3). PMID: 18435612    Free PMC article.
Highly Cited. Review.
M-1/M-2 macrophages and the Th1/Th2 paradigm.
C D Mills, K Kincaid, +2 authors, A M Hill.
J Immunol, 2000 Jun 08; 164(12). PMID: 10843666
Highly Cited.
Spontaneous melanocytosis in transgenic mice.
S Chen, H Zhu, W J Wetzel, M A Philbert.
J Invest Dermatol, 1996 May 01; 106(5). PMID: 8618055
A guide to cancer immunotherapy: from T cell basic science to clinical practice.
Alex D Waldman, Jill M Fritz, Michael J Lenardo.
Nat Rev Immunol, 2020 May 21; 20(11). PMID: 32433532    Free PMC article.
Review.
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, +17 authors, Keith T Flaherty.
Lancet Oncol, 2018 Mar 27; 19(5). PMID: 29573941
Highly Cited.
Prospects of IL-2 in Cancer Immunotherapy.
Hani Choudhry, Nawal Helmi, +7 authors, Mohammad S Jamal.
Biomed Res Int, 2018 Jun 02; 2018. PMID: 29854806    Free PMC article.
Review.
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Alexander C Huang, Michael A Postow, +31 authors, E John Wherry.
Nature, 2017 Apr 12; 545(7652). PMID: 28397821    Free PMC article.
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
Ana B del Campo, Jon Amund Kyte, +8 authors, Natalia Aptsiauri.
Int J Cancer, 2013 Jun 21; 134(1). PMID: 23784959
Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma.
Allison L Isola, Kevinn Eddy, Suzie Chen.
Cancers (Basel), 2016 Dec 13; 8(12). PMID: 27941674    Free PMC article.
Review.
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.
Lewis Zhichang Shi, Sangeeta Goswami, +12 authors, Padmanee Sharma.
Cancer Immunol Res, 2019 Aug 31; 7(11). PMID: 31466995
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
A Kamb, D Shattuck-Eidens, +7 authors, J Weaver-Feldhaus.
Nat Genet, 1994 Sep 01; 8(1). PMID: 7987388
Highly Cited.
Surgery of primary tumor improves the survival of newly diagnosed metastatic melanoma: a population-based, propensity-matched study.
Dongxiao Zhang, Yinjun Dong, +2 authors, Jinming Yu.
Cancer Manag Res, 2019 Jan 16; 11. PMID: 30643459    Free PMC article.
Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model.
David G Mairhofer, Daniela Ortner, +10 authors, Patrizia Stoitzner.
J Invest Dermatol, 2015 Jun 30; 135(11). PMID: 26121214    Free PMC article.
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
Brian T Fife, Kristen E Pauken, +6 authors, Jeffrey A Bluestone.
Nat Immunol, 2009 Sep 29; 10(11). PMID: 19783989    Free PMC article.
Highly Cited.
Death through a tragedy: mitotic catastrophe.
H Vakifahmetoglu, M Olsson, B Zhivotovsky.
Cell Death Differ, 2008 Apr 12; 15(7). PMID: 18404154
Highly Cited. Review.
Magnetic resonance imaging of melanoma exosomes in lymph nodes.
Lingzhi Hu, Samuel A Wickline, Joshua L Hood.
Magn Reson Med, 2014 Jul 24; 74(1). PMID: 25052384    Free PMC article.
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.
Tadashi Yokosuka, Masako Takamatsu, +3 authors, Takashi Saito.
J Exp Med, 2012 May 30; 209(6). PMID: 22641383    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Bertrand Routy, Emmanuelle Le Chatelier, +45 authors, Laurence Zitvogel.
Science, 2017 Nov 04; 359(6371). PMID: 29097494
Highly Cited.
FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor.
Connull Leslie, Samantha E Bowyer, +5 authors, Michael Millward.
Pathology, 2015 Aug 27; 47(6). PMID: 26308130
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Michael Krauthammer, Yong Kong, +27 authors, Ruth Halaban.
Nat Genet, 2012 Jul 31; 44(9). PMID: 22842228    Free PMC article.
Highly Cited.
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.
T Kageshita, S Hirai, +2 authors, S Ferrone.
Am J Pathol, 1999 Mar 18; 154(3). PMID: 10079252    Free PMC article.
Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells.
Joel Baumgartner, Cara Wilson, +3 authors, Martin McCarter.
J Surg Res, 2007 Jun 19; 141(1). PMID: 17574040    Free PMC article.
Melanoma exosomes promote mixed M1 and M2 macrophage polarization.
Gina T Bardi, Mary Ann Smith, Joshua L Hood.
Cytokine, 2018 Feb 21; 105. PMID: 29459345    Free PMC article.
Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets.
Laurent Muller, Masato Mitsuhashi, +2 authors, Theresa L Whiteside.
Sci Rep, 2016 Feb 05; 6. PMID: 26842680    Free PMC article.
Highly Cited.
Biomarkers for Immune Checkpoint Inhibitors in Melanoma.
Shigehisa Kitano, Takayuki Nakayama, Makiko Yamashita.
Front Oncol, 2018 Aug 04; 8. PMID: 30073150    Free PMC article.
Review.
Distinct sets of genetic alterations in melanoma.
John A Curtin, Jane Fridlyand, +9 authors, Boris C Bastian.
N Engl J Med, 2005 Nov 18; 353(20). PMID: 16291983
Highly Cited.
The use of interferon in melanoma patients: a systematic review.
Rossella Di Trolio, Ester Simeone, +2 authors, Paolo Antonio Ascierto.
Cytokine Growth Factor Rev, 2014 Dec 17; 26(2). PMID: 25511547
Systematic Review.
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.
Annika De Sousa Linhares, Claire Battin, +8 authors, Peter Steinberger.
Sci Rep, 2019 Aug 09; 9(1). PMID: 31391510    Free PMC article.
B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim.
Rachel M Gibbons, Xin Liu, +4 authors, Haidong Dong.
Oncoimmunology, 2012 Nov 22; 1(7). PMID: 23170254    Free PMC article.
Decoding melanoma metastasis.
William E Damsky, Lara E Rosenbaum, Marcus Bosenberg.
Cancers (Basel), 2010 Jan 01; 3(1). PMID: 24212610    Free PMC article.
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
Sergei Kusmartsev, Yulia Nefedova, Daniel Yoder, Dmitry I Gabrilovich.
J Immunol, 2004 Jan 07; 172(2). PMID: 14707072
Highly Cited.
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz, Daniel Sanghoon Shin, +16 authors, Antoni Ribas.
Cell Rep, 2017 May 13; 19(6). PMID: 28494868    Free PMC article.
Highly Cited.
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.
Derek Ng Tang, Yu Shen, +5 authors, Padmanee Sharma.
Cancer Immunol Res, 2014 Apr 30; 1(4). PMID: 24777852    Free PMC article.
Highly Cited.
[THE EPIDERMAL MELANIN UNIT SYSTEM].
T B FITZPATRICK, A S BREATHNACH.
Dermatol Wochenschr, 1963 May 18; 147. PMID: 14172128
Highly Cited.
Specific inhibition of PI3K p110δ inhibits CSF-1-induced macrophage spreading and invasive capacity.
Kellie A Mouchemore, Natalia G Sampaio, +3 authors, Fiona J Pixley.
FEBS J, 2013 May 08; 280(21). PMID: 23648053    Free PMC article.
Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, +72 authors, Michael R Stratton.
Nature, 2013 Aug 16; 500(7463). PMID: 23945592    Free PMC article.
Highly Cited.
Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells.
Priyanka Sharma, Brenda Diergaarde, +2 authors, Theresa L Whiteside.
Sci Rep, 2020 Jan 11; 10(1). PMID: 31919420    Free PMC article.
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
Jun Zhang, L Jeffrey Medeiros, Ken H Young.
Front Oncol, 2018 Sep 27; 8. PMID: 30250823    Free PMC article.
Review.
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Gerald S Falchook, Karl D Lewis, +19 authors, Leslie A Fecher.
Lancet Oncol, 2012 Jul 19; 13(8). PMID: 22805292    Free PMC article.
Highly Cited.
In vitro reactivity of splenic lymphocytes from normal and UV-irradiated mice against syngeneic UV-induced tumors.
G W Fortner, M L Kripke.
J Immunol, 1977 Apr 01; 118(4). PMID: 66296
Does exposure to UV radiation induce a shift to a Th-2-like immune reaction?
S E Ullrich.
Photochem Photobiol, 1996 Aug 01; 64(2). PMID: 8760564
Review.
Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Jennifer D Hintzsche, Nicholas T Gorden, +16 authors, William A Robinson.
Melanoma Res, 2017 Mar 16; 27(3). PMID: 28296713    Free PMC article.
Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults.
Jacqueline Dinnes, Jonathan J Deeks, +15 authors, Cochrane Skin Cancer Diagnostic Test Accuracy Group.
Cochrane Database Syst Rev, 2018 Dec 07; 12. PMID: 30521682    Free PMC article.
Highly Cited. Systematic Review.
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
Alexander M Menzies, Lauren E Haydu, +6 authors, Georgina V Long.
Clin Cancer Res, 2012 Apr 27; 18(12). PMID: 22535154
Highly Cited.
Surgery of primary melanomas.
Piotr Rutkowski, Marcin Zdzienicki, Zbigniew I Nowecki, Alexander C J Van Akkooi.
Cancers (Basel), 2010 Jan 01; 2(2). PMID: 24281096    Free PMC article.
Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation.
Nikolaos Patsoukis, Jonathan S Duke-Cohan, +6 authors, Vassiliki A Boussiotis.
Commun Biol, 2020 Mar 19; 3(1). PMID: 32184441    Free PMC article.
Gender-related differences in outcome for melanoma patients.
Charles R Scoggins, Merrick I Ross, +13 authors, Sunbelt Melanoma Trial.
Ann Surg, 2006 Apr 25; 243(5). PMID: 16633005    Free PMC article.
Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chien-Chung Chang, Giuseppe Pirozzi, +6 authors, Soldano Ferrone.
J Biol Chem, 2015 Sep 19; 290(44). PMID: 26381407    Free PMC article.
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
Robert H I Andtbacka, Merrick Ross, +10 authors, Howard L Kaufman.
Ann Surg Oncol, 2016 Nov 03; 23(13). PMID: 27342831    Free PMC article.
Highly Cited.
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Richard A Morgan, Mark E Dudley, +13 authors, Steven A Rosenberg.
Science, 2006 Sep 02; 314(5796). PMID: 16946036    Free PMC article.
Highly Cited.
Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Eva Schlecker, Ana Stojanovic, +4 authors, Adelheid Cerwenka.
J Immunol, 2012 Nov 16; 189(12). PMID: 23152559
Highly Cited.
Chemotherapy for Melanoma.
Melissa A Wilson, Lynn M Schuchter.
Cancer Treat Res, 2015 Nov 26; 167. PMID: 26601864
Review.
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
Fumiya Hirano, Katsumi Kaneko, +9 authors, Lieping Chen.
Cancer Res, 2005 Feb 12; 65(3). PMID: 15705911
Highly Cited.
Histologic features of tumors and the female superiority in survival from malignant melanoma.
H M Shaw, V J McGovern, +2 authors, W H McCarthy.
Cancer, 1980 Apr 01; 45(7). PMID: 7370919
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.
Sonja Kleffel, Christian Posch, +19 authors, Tobias Schatton.
Cell, 2015 Sep 12; 162(6). PMID: 26359984    Free PMC article.
Highly Cited.
Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.
Jin Namkoong, Seung-Shick Shin, +4 authors, Suzie Chen.
Cancer Res, 2007 Mar 03; 67(5). PMID: 17332361
Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Patrizia Stoitzner, Laura K Green, +4 authors, Franca Ronchese.
Cancer Immunol Immunother, 2008 Mar 04; 57(11). PMID: 18311487
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.
A Nazmul H Khan, Christopher J Gregorie, Thomas B Tomasi.
Cancer Immunol Immunother, 2007 Nov 30; 57(5). PMID: 18046553    Free PMC article.
Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function.
Cunren Liu, Shaohua Yu, +8 authors, Huang-Ge Zhang.
J Immunol, 2006 Jan 21; 176(3). PMID: 16424164
Highly Cited.
Current state of melanoma diagnosis and treatment.
Lauren E Davis, Sara C Shalin, Alan J Tackett.
Cancer Biol Ther, 2019 Aug 02; 20(11). PMID: 31366280    Free PMC article.
Review.
Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok.
Science, 2018 Mar 24; 359(6382). PMID: 29567705    Free PMC article.
Highly Cited. Review.
Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod.
Margarete Schön, Anne B Bong, +7 authors, Michael P Schön.
J Natl Cancer Inst, 2003 Aug 07; 95(15). PMID: 12902443
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Y Latchman, C R Wood, +18 authors, G J Freeman.
Nat Immunol, 2001 Feb 27; 2(3). PMID: 11224527
Highly Cited.
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Sumit K Subudhi, Ana Aparicio, +14 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2016 Oct 30; 113(42). PMID: 27698113    Free PMC article.
Highly Cited.
Integrating oncolytic viruses in combination cancer immunotherapy.
Praveen K Bommareddy, Megha Shettigar, Howard L Kaufman.
Nat Rev Immunol, 2018 May 11; 18(8). PMID: 29743717
Highly Cited. Review.
CTLA-4 is a second receptor for the B cell activation antigen B7.
P S Linsley, W Brady, +3 authors, J A Ledbetter.
J Exp Med, 1991 Sep 01; 174(3). PMID: 1714933    Free PMC article.
Highly Cited.
Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis.
Joshua L Hood, Roman Susana San, Samuel A Wickline.
Cancer Res, 2011 Apr 12; 71(11). PMID: 21478294
Highly Cited.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, +3 authors, Ana C Anderson.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819927    Free PMC article.
Highly Cited.
Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy.
Xiaoying Sun, Na Zhang, +2 authors, Xin Li.
Front Oncol, 2020 Jul 28; 10. PMID: 32714859    Free PMC article.
Review.
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Spencer C Wei, Nana-Ama A S Anang, +8 authors, James P Allison.
Proc Natl Acad Sci U S A, 2019 Oct 23; 116(45). PMID: 31636208    Free PMC article.
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy.
Ioana Plesca, Antje Tunger, +6 authors, Marc Schmitz.
Front Immunol, 2020 Mar 21; 11. PMID: 32194568    Free PMC article.
Review.
Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells.
H Groux, M Bigler, J E de Vries, M G Roncarolo.
J Immunol, 1998 Apr 08; 160(7). PMID: 9531274
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Frank Stephen Hodi, Vanna Chiarion-Sileni, +16 authors, Jedd D Wolchok.
Lancet Oncol, 2018 Oct 27; 19(11). PMID: 30361170
Highly Cited.
Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment.
A Serrano, S Tanzarella, +4 authors, F Garrido.
Int J Cancer, 2001 Oct 23; 94(2). PMID: 11668505
Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vinicius de Lima Vazquez, Anna L Vicente, +5 authors, Rui M Reis.
Melanoma Res, 2015 Dec 29; 26(2). PMID: 26709572
BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
D L Morton, F R Eilber, +4 authors, F C Sparks.
Ann Surg, 1974 Oct 01; 180(4). PMID: 4412271    Free PMC article.
Highly Cited.
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
Subhra K Biswas, Alberto Mantovani.
Nat Immunol, 2010 Sep 22; 11(10). PMID: 20856220
Highly Cited. Review.
Germline p16 mutations in familial melanoma.
C J Hussussian, J P Struewing, +6 authors, N C Dracopoli.
Nat Genet, 1994 Sep 01; 8(1). PMID: 7987387
Highly Cited.
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
P A van der Merwe, D L Bodian, +2 authors, S J Davis.
J Exp Med, 1997 Feb 03; 185(3). PMID: 9053440    Free PMC article.
Highly Cited.
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.
Amanda R Moore, Emilie Ceraudo, +11 authors, Yu Chen.
Nat Genet, 2016 Apr 19; 48(6). PMID: 27089179    Free PMC article.
Highly Cited.
M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment.
Eva Van Overmeire, Benoît Stijlemans, +12 authors, Damya Laoui.
Cancer Res, 2015 Nov 18; 76(1). PMID: 26573801
Highly Cited.
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Chrysoula I Liakou, Ashish Kamat, +5 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2008 Sep 27; 105(39). PMID: 18818309    Free PMC article.
Highly Cited.
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.
Yoshiyuki Nakamura.
Front Med (Lausanne), 2019 Jun 14; 6. PMID: 31192215    Free PMC article.
Review.
Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
Wonjin Chang, Su Jin Lee, +7 authors, Jeeyun Lee.
Melanoma Res, 2013 Feb 16; 23(2). PMID: 23411477
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Keith T Flaherty, Jeffery R Infante, +23 authors, Jeffrey Weber.
N Engl J Med, 2012 Oct 02; 367(18). PMID: 23020132    Free PMC article.
Highly Cited.
Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.
L Lauerova, L Dusek, +4 authors, J Kovarík.
Neoplasma, 2002 Jul 05; 49(3). PMID: 12098001
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, +6 authors, Razelle Kurzrock.
Mol Cancer Ther, 2017 Aug 25; 16(11). PMID: 28835386    Free PMC article.
Highly Cited.
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.
Joseph M Obeid, Gulsun Erdag, +5 authors, Craig L Slingluff.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999753    Free PMC article.
CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation.
Xiong B Wang, Zhong Z Fan, +4 authors, Ann K Lefvert.
BMC Immunol, 2011 Mar 19; 12. PMID: 21414236    Free PMC article.
Langerhans cells are required for UVR-induced immunosuppression.
Agatha Schwarz, Madelon Noordegraaf, +3 authors, Thomas Schwarz.
J Invest Dermatol, 2010 Jan 22; 130(5). PMID: 20090769
Adoptive cell therapy: genetic modification to redirect effector cell specificity.
Richard A Morgan, Mark E Dudley, Steven A Rosenberg.
Cancer J, 2010 Aug 10; 16(4). PMID: 20693844    Free PMC article.
Review.
The melanocyte lineage in development and disease.
Richard L Mort, Ian J Jackson, E Elizabeth Patton.
Development, 2015 Feb 12; 142(4). PMID: 25670789    Free PMC article.
Highly Cited. Review.
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.
Kristen E Pauken, Morgan A Sammons, +16 authors, E John Wherry.
Science, 2016 Oct 30; 354(6316). PMID: 27789795    Free PMC article.
Highly Cited.
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
F Stephen Hodi, Christopher L Corless, +21 authors, David E Fisher.
J Clin Oncol, 2013 Jun 19; 31(26). PMID: 23775962    Free PMC article.
Highly Cited.
The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening.
J J Grob, J J Bonerandi.
Arch Dermatol, 1998 Feb 05; 134(1). PMID: 9449921
Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.
Elizabeth Ann L Enninga, Wendy K Nevala, +2 authors, Svetomir N Markovic.
Melanoma Res, 2016 Jul 28; 26(5). PMID: 27455380    Free PMC article.
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Zeynep Eroglu, Dae Won Kim, +9 authors, Antoni Ribas.
Eur J Cancer, 2015 Sep 15; 51(17). PMID: 26364516    Free PMC article.
Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.
Porcia T Bradford, Alisa M Goldstein, Mary L McMaster, Margaret A Tucker.
Arch Dermatol, 2009 Apr 22; 145(4). PMID: 19380664    Free PMC article.
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma.
Carlos A Morales-Betanzos, Hyoungjoo Lee, +4 authors, Daniel C Liebler.
Mol Cell Proteomics, 2017 May 27; 16(10). PMID: 28546465    Free PMC article.
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Omid Hamid, Henrik Schmidt, +9 authors, David Berman.
J Transl Med, 2011 Nov 30; 9. PMID: 22123319    Free PMC article.
Highly Cited.
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Mauro Poggio, Tianyi Hu, +8 authors, Robert Blelloch.
Cell, 2019 Apr 06; 177(2). PMID: 30951669    Free PMC article.
Highly Cited.
Dermoscopy for melanoma detection in family practice.
Andrea Herschorn.
Can Fam Physician, 2012 Aug 04; 58(7). PMID: 22859635    Free PMC article.
Review.
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Matteo S Carlino, Alexander M Menzies, +16 authors, Georgina V Long.
Clin Cancer Res, 2020 Jul 02; 26(19). PMID: 32605909
UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin.
Taketsugu Tadokoro, Nobuhiko Kobayashi, +7 authors, Vincent J Hearing.
FASEB J, 2003 Apr 15; 17(9). PMID: 12692083
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
F M Marincola, Y M Hijazi, +8 authors, S A Rosenberg.
J Immunother Emphasis Tumor Immunol, 1996 May 01; 19(3). PMID: 8811494
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, +16 authors, Antoni Ribas.
N Engl J Med, 2014 Sep 30; 371(20). PMID: 25265494
Highly Cited.
Induction of myeloid-derived suppressor cells by tumor exosomes.
Xiaoyu Xiang, Anton Poliakov, +10 authors, Huang-Ge Zhang.
Int J Cancer, 2009 Feb 25; 124(11). PMID: 19235923    Free PMC article.
Highly Cited.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, +18 authors, Paul B Chapman.
Lancet, 2012 Jun 28; 380(9839). PMID: 22735384
Highly Cited.
Whole-genome landscapes of major melanoma subtypes.
Nicholas K Hayward, James S Wilmott, +46 authors, Graham J Mann.
Nature, 2017 May 04; 545(7653). PMID: 28467829
Highly Cited.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, +32 authors, Keith Flaherty.
N Engl J Med, 2014 Sep 30; 371(20). PMID: 25265492
Highly Cited.
Immune-related adverse events of checkpoint inhibitors.
Manuel Ramos-Casals, Julie R Brahmer, +7 authors, Maria E Suárez-Almazor.
Nat Rev Dis Primers, 2020 May 10; 6(1). PMID: 32382051
Review.
Pathways and therapeutic targets in melanoma.
Emma Shtivelman, Michael Q A Davies, +5 authors, David E Fisher.
Oncotarget, 2014 Apr 20; 5(7). PMID: 24743024    Free PMC article.
Highly Cited. Review.
Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma.
Wan Zhang, Zhenghui Song, +5 authors, Aimin Li.
J Cancer, 2019 Jul 02; 10(11). PMID: 31258764    Free PMC article.
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
Floris Dammeijer, Mandy van Gulijk, +21 authors, Joachim G Aerts.
Cancer Cell, 2020 Oct 03; 38(5). PMID: 33007259
Therapeutic opportunities in noncutaneous melanoma.
D K Wilkins, P D Nathan.
Ther Adv Med Oncol, 2009 Jul 01; 1(1). PMID: 21789111    Free PMC article.
Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways.
Patrick L Raber, Paul Thevenot, +9 authors, Paulo C Rodriguez.
Int J Cancer, 2013 Nov 22; 134(12). PMID: 24259296    Free PMC article.
Number of melanocytic nevi as a major risk factor for malignant melanoma.
E A Holly, J W Kelly, S N Shpall, S H Chiu.
J Am Acad Dermatol, 1987 Sep 01; 17(3). PMID: 3655025
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
Mohammad Atefi, Earl Avramis, +9 authors, Antoni Ribas.
Clin Cancer Res, 2014 May 09; 20(13). PMID: 24812408    Free PMC article.
Highly Cited.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.
Zeynep Eroglu, Antoni Ribas.
Ther Adv Med Oncol, 2016 Jan 12; 8(1). PMID: 26753005    Free PMC article.
Highly Cited. Review.
KIT is a frequent target for epigenetic silencing in cutaneous melanoma.
Christina Dahl, Cecilie Abildgaard, +3 authors, Per Guldberg.
J Invest Dermatol, 2014 Sep 02; 135(2). PMID: 25178104
Treatment of locally recurrent mucosal melanoma with topical imiquimod.
Elizabeth C Smyth, Marisa Flavin, +8 authors, Richard D Carvajal.
J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010009
CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases.
Christine Guntermann, Denis R Alexander.
J Immunol, 2002 Apr 24; 168(9). PMID: 11970985
The Erk2 MAPK regulates CD8 T cell proliferation and survival.
Warren N D'Souza, Chiung-Fang Chang, +2 authors, Stephen M Hedrick.
J Immunol, 2008 Nov 20; 181(11). PMID: 19017950    Free PMC article.
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
Joel C Sunshine, Peter L Nguyen, +10 authors, Janis M Taube.
Clin Cancer Res, 2017 Apr 22; 23(16). PMID: 28428193    Free PMC article.
Highly Cited.
T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells.
Keishi Adachi, Mark M Davis.
Proc Natl Acad Sci U S A, 2011 Jan 06; 108(4). PMID: 21205892    Free PMC article.
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities.
Kevinn Eddy, Raj Shah, Suzie Chen.
Front Oncol, 2021 Feb 23; 10. PMID: 33614507    Free PMC article.
Review.
OX40L-OX40 Signaling in Atopic Dermatitis.
Masutaka Furue, Mihoko Furue.
J Clin Med, 2021 Jul 03; 10(12). PMID: 34208041    Free PMC article.
The Efficacy of Anti-PD-L1 Treatment in Melanoma Is Associated with the Expression of the ECM Molecule EMILIN2.
Albina Fejza, Maurizio Polano, +5 authors, Eva Andreuzzi.
Int J Mol Sci, 2021 Jul 25; 22(14). PMID: 34299131    Free PMC article.
Microbeam Radiotherapy-A Novel Therapeutic Approach to Overcome Radioresistance and Enhance Anti-Tumour Response in Melanoma.
Verdiana Trappetti, Jennifer M Fazzari, +4 authors, Valentin G Djonov.
Int J Mol Sci, 2021 Jul 25; 22(14). PMID: 34299373    Free PMC article.
Review.
Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma.
Kevinn Eddy, Suzie Chen.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359771    Free PMC article.
Review.
Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up.
Sara Saellstrom, Arian Sadeghi, +7 authors, Henrik Ronnberg.
Front Vet Sci, 2021 Aug 10; 8. PMID: 34368282    Free PMC article.
Unraveling the Wide Spectrum of Melanoma Biomarkers.
Antonios Revythis, Sidrah Shah, +7 authors, Stergios Boussios.
Diagnostics (Basel), 2021 Aug 28; 11(8). PMID: 34441278    Free PMC article.
Review.
Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Mohamad Hamieh, Jean-François Chatillon, +8 authors, Jean-Baptiste Latouche.
Front Immunol, 2021 Sep 28; 12. PMID: 34566953    Free PMC article.
Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma.
Elena-Georgiana Dobre, Carolina Constantin, Marieta Costache, Monica Neagu.
J Pers Med, 2021 Sep 29; 11(9). PMID: 34575678    Free PMC article.
Review.
FKBP51 Affects TNF-Related Apoptosis Inducing Ligand Response in Melanoma.
Martina Tufano, Elena Cesaro, +3 authors, Maria Fiammetta Romano.
Front Cell Dev Biol, 2021 Oct 01; 9. PMID: 34589486    Free PMC article.
Preclinical Study of Immunological Isoxazole Derivatives as a Potential Support for Melanoma Chemotherapy.
Izabela Jęśkowiak, Benita Wiatrak, Adam Szeląg, Marcin Mączyński.
Int J Mol Sci, 2021 Oct 24; 22(20). PMID: 34681580    Free PMC article.
Novel possibility for cutaneous melanoma treatment by means of rosmarinic acid action on purinergic signaling.
Gilnei Bruno da Silva, Milena Ayumi Yamauchi, Daniela Zanini, Margarete Dulce Bagatini.
Purinergic Signal, 2021 Nov 07; 18(1). PMID: 34741236    Free PMC article.
Review.
Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study.
Morten Fink, Anders Schwartz Vittrup, +10 authors, Henrik Schmidt.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771712    Free PMC article.
Comprehensive Analysis of the Immune Implication of TEX41 in Skin Cutaneous Melanoma.
Zhi-Yong Chen, Jie-Qing Huang, +2 authors, Xue-Feng Yu.
Dis Markers, 2021 Nov 20; 2021. PMID: 34795805    Free PMC article.
Oxidative Stress and Autophagy as Key Targets in Melanoma Cell Fate.
Elisabetta Catalani, Matteo Giovarelli, +2 authors, Davide Cervia.
Cancers (Basel), 2021 Nov 28; 13(22). PMID: 34830947    Free PMC article.
Review.
The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.
Mariana Matias, Jacinta O Pinho, +3 authors, Maria Manuela Gaspar.
Cells, 2021 Nov 28; 10(11). PMID: 34831311    Free PMC article.
Review.
Identification of m6A Regulator-Associated Methylation Modification Clusters and Immune Profiles in Melanoma.
Fengying Du, Han Li, +10 authors, Xiaokang Li.
Front Cell Dev Biol, 2022 Jan 08; 9. PMID: 34993195    Free PMC article.
Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma.
Francesca Comito, Rachele Pagani, +3 authors, Barbara Melotti.
Cancers (Basel), 2022 Jan 22; 14(2). PMID: 35053435    Free PMC article.
Review.
Nobiletin Induces Ferroptosis in Human Skin Melanoma Cells Through the GSK3β-Mediated Keap1/Nrf2/HO-1 Signalling Pathway.
Senling Feng, Yongheng Zhou, +8 authors, Baoying Liang.
Front Genet, 2022 Mar 31; 13. PMID: 35350242    Free PMC article.
Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016).
Asad Loya, Dan S Gombos, Sapna P Patel.
Front Oncol, 2022 Apr 05; 12. PMID: 35372013    Free PMC article.
The Role of Fast-Cycling Atypical RHO GTPases in Cancer.
Pontus Aspenström.
Cancers (Basel), 2022 Apr 24; 14(8). PMID: 35454871    Free PMC article.
Review.